Large clones in TP53, DNMT3A, TET2, and splicing factor genes [13,14], the presence of two or more mutations (versus a single one) in DNMT3A [13], and the presence of additional driver mutations [14,15], are associated with higher risk of progression to AML. This evidence concerns the gene TP53 and acute myeloid leukemia.